408 .00 €
Food for Special Medical Purposes for Cancer Patients
What is Culevit Forte for Cancer Patients Powder for Oral Solution?
Culevit Forte for Cancer Patients Powder for Oral Solution is a unique, scientifically improved, newly patented product for supplementing and supporting conventional oncological therapies. Culevit Forte Powder is a Hungarian product manufactured in a pharmaceutical factory in Hungary.
The active components of the powder are all essential, important and natural substances that can also be found in the human body. Continuous consumption of Culevit Forte products ensures the increased intake of these substances.
Culevit Forte for Cancer Patients Powder for Oral Solution has no adverse effects and can be taken in combination with any medicine or other complementary health products.
The composition of the powder is identical to the composition of Culevit Forte for Cancer Patients Tablet.
1 sachet of Culevit Forte for Cancer Patients Powder for Oral Solution equals to 30 Culevit Forte for Cancer Patients tablets.
The advantage of the powder form is the easy absorption and the absence of excipients. It is especially beneficial for those patients who have difficulties in swallowing therefore they are unable to take Culevit Forte for Cancer Patients Tablet. It is also recommended for those cancer patients whose condition is very serious because they need to use Culevit Forte Powder in the highest possible dosage (2 sachets/day).
Whom and why is Culevit Forte Powder for Oral Solution recommended for?
Culevit Forte Powder for Oral Solution is recommended for cancer patients to complement their conventional oncological therapies. (Ie. radiation and chemotherapies).
How and when should the product be administered?
The recommended dose for a cancer patient is 1-2 sachets/day, taken once every hour, evenly distributed throughout the day, from waking up until going to sleep.
1-2 sachets of powder should be dissolved in 600 ml of non-carbonated water while stirring continuously. Cancer patients are advised to drink 50 ml of this solution every hour during the day (12 x 50 ml a day). The powder should be administered continuously, without interruption before, during and after oncology treatments. As long as the tumour is still detectable, the product should be used continuously (1–2 sachets/day). If the tumour can no longer be traced, it is advised to continue the administration of the powder: for 6 more months with a required dosage of 1–2 sachets/day, then for at least another 6 months with 1 sachet/day.
Why is it important to take Culevit Forte Powder for Oral Solution every hour?
The concentration of the active ingredients of Culevit Forte Powder will reach its peak in the circulatory system in approximately 1 hour after its consumption and will be discharged gradually hence the concentration returns to the baseline in approx. 2-3 hours. Since the aim is to keep the concentration of the active substances at a consistently high level in the body, the product should be taken hourly. It is not advisable to take Culevit Forte Powder after bedtime, as the stress of having to wake up every hour throughout the night would deprive the patient of a much needed rest and can cause high level of stress.
When should the administration of the product be avoided?
If you are allergic to any of the ingredients or excipients you should not consume the product! Patients with phenylketonuria should not administer it because the product contains Phenylalanine. Avoid using the product in case of hyperhomocysteinemia and homocystinuria because it contains Methionine. Patients with severe liver or kidney disease should consult their doctor before taking the product.
What do we know about Culevit Forte Powder for Oral Solution?
One box contains 30 sachets which is the recommended amount for 30 days (1 month). However, if you take the highest dosage (2 sachets/day) then this amount is enough only for 15 days.
Where can Culevit Forte Powder for Oral Solution be purchased?
Culevit Forte Powder for Oral Solution can be purchased through our webshop, click here.
Notification number: T/1907/2014